The Evidence Summary of Drug Safety Evaluation in the Cochrane Collaboration

Abstract

Abstract: Objective To summarize the evidence related to drug safety available from the Cochrane Collaboration. Methods Electronic searching on the Cochrane Library(2009 Issue 3), the searching terms included adverse drug reaction and drug safety. Results ＆Condusion Articles related to 6 aspects including Cochrane systematic review, abstracts of non-Cochrane systematic review, clinical trials, methodological study, health technology assessment and economical evaluation, respectively, were reviewed. The safety was evaluated along with efficacy or effectiveness of drugs. Currently, there has been no specific systematic review focusing on drug safety in the Cochrane Collaboration.

Key words: The Cochrane Collaboration, drug safety, evaluation, evidence, summary

CLC Number:

R954

XIA Yun, LI Xin-xue, LIU Jian-ping. The Evidence Summary of Drug Safety Evaluation in the Cochrane Collaboration[J]. Chinese Journal of Pharmacovigilance, 2010, 7(4): 208-210.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2010/V7/I4/208

References

[1] http://www.interscience.wiley.com/cgi-bin/mrwhome/106568753/home.
[2] http://www.mrw.interscience.wiley.com/cochrane/cochrane_clabout_contents_fs.html .
[3] Loke Y K, Price D, Herxheimer A. Chapter 14: Adverse effects. In: Higgins JPT, Green S(editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1(updated September 2008)[S]. The Cochrane Collaboration, 2008.
[4] Zhang W Y. Evidence from case-control and cohort studies for adverse drug reaction - a case study of analgesic nephropathy[R].9th Annual Cochrane Colloquium Abstracts, 2001.
[5] Golder S, Loke Y, McIntosh H. Going beyond MEDLINE - what information might reviewers find from searching databases of adverse drug reactions?[J].XIV Cochrane Colloquium, 2006, 10: 23-26;Dublin, Ireland. 2006,44.
[6] Nilsson BS. Evaluation of methods for recording adverse drug reactions in clinical trials[J]. European Journal of Clinical Microbio-logy & Infectious Disease, 1990,89(7):534-536.
[7] Wallin J, Sjovall J. Detection of adverse drug reactions in a clinical trial using two types of questioning [J]. Clinical Therapeutics, 1981,3(6):450-452.
[8] Agbabiaka T B, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review[J]. Drug safety, 2008,31(1):21-37.
[9] Aronson J K, Derry S, Loke Y K. Adverse drug reactions: keeping up to date[J]. Fundamental & Clinical Pharmacology, 2002,16(1):49-56.
[10] Venulet J, Blattner R, Von Bulow J, et al. How good are articles on adverse drug reactions?[J]BMJ,1982,284(6311):252-254.
[11] Loke Y K, Price D, Derry S, et al. Case reports of suspected adverse drug reactions-systematic literature survey of followup[J]. BMJ, 2006,332(7573):335-339.
[12] Hazell L, Shakir S A. Under-reporting of adverse drug reactions: a systematic review[J]. Drug Safety, 2006,29(5):385-396.

[1]	SHEN Chen, ZHOU Xian, LIU Jianping. Database and Evaluation Methods for Chinese Herb-Drug Interactions [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908.
[2]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[3]	REN Yuke, QU Zhe, LAI Zixuan, ZHANG Di, ZHAO Yongtian, YANG Yanwei, LI Shuangxing, HUO Guitao, ZHOU Xiaobing, LIN Zhi, GENG Xingchao. Pharmacodynamic Evaluation of CAR-T Cell Products Based on Deep Learning Convolutional Neural Network Recognition [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 742-748.
[4]	ZHANG Huiting, LI Youlin, LI Lei, YAN Yue, YAO Ting, LI Chunlei, SHI Qi. Toxicity of Single-Dose and Repeated-Dose Administration of Guisha Zichuan Granules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 547-553.
[5]	WANG Jiaqing, WANG Qi, LIU Tongtong, ZHANG Dongjie, NING Xiao. Uncertainty Evaluation for the Determination of Tacrolimus Content in Human Whole Blood by UPLC-MS/MS Method [J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 386-390.
[6]	LI Bo, XU Liu, XIE Yuqing, WANG Yiying, DONG Shuai, LIAN Jie, LI Guodong, CAO Huijuan. Safety and Efficacy of Chinese Herbal Patent Medicines for COVID-19: an Umbrella Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 155-161.
[7]	ZHENG Changhui, MA Lina, HE Ting, GU Yuanyuan, ZHAO Wei, WANG Hongbin, NIU Yuanfei, FU Yao, CHEN Yanjun, CAO Junling. Quality Evaluation and Control of Bupleuri Radix Decoction Pieces Based on ‘Shape-Chemistry-Biology' Sequential Detection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 197-205.
[8]	NIE Xiaolu, ZHAO Houyu, HUO Donghui, YAN Aixia, SUN Feng, PENG Xiaoxia, NI Xin, ZHAN Siyan. Pediatric Drug-Induced Immune Thrombocytopenia Based on Real World Data and Quantitative Structure-Activity Relationship [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 16-22.
[9]	JIA Juanjuan, SUN Jiabei, ZHANG Wenzai, SUN Deyang, SHI Yaqin, HUANG Haiwei. Biological Distribution of ^99mTc-DMSA Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 47-52.
[10]	LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
[11]	WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo. Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
[12]	ZHENG Li, ZHANG Kaihua, SUN Xuelin. Pharmacological effect and clinical evaluation of tarlatamab against small cell lung cancer [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1078-1080.
[13]	SUN Li, XIE Bin, XU Yanqin. Research progress of sustained and controlled release preparations of Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 949-954.
[14]	LIU Yadi, ZHANG Xiaomeng, CAI Haili, CHEN Siying, WANG Yu, ZHANG Bing. Traditional Chinese medicine for prevention and treatment of adriamycin cardiotoxicity and an empirical study of evidence elements [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 759-764.
[15]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, LIU Shujia, GAO Fujun, WANG Yu, ZHANG Bing. Progress in construction and evaluation of a drug-induced cardiotoxicity model [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 765-770.